Milpharm Limited Issues Class 4 Medicines Defect Notification for Loperamide Hydrochloride
A discrepancy has been identified in the Patient Information Leaflet for Loperamide hydrochloride 2 mg Orodispersible Tablets.
Asset / Drug
Drug and asset intelligence for Milpharm with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.